Pancreatic Cancer Research

ResearcherNorthern Jiangsu People's HospitalNo recent work listed

Zhennan Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0008-5886-1651; OpenAlex author ID A5101652594. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
12
Papers, trials and grants by year

2016: 3 papers · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: 2 papers

Papers 10

  1. The long non-coding RNA EGOT promotes pancreatic cancer progression by sequestering miR-214 to derepress PLS3 expression Co-author DOI 10.21203/rs.3.rs-1415870/v1↗
  2. FAM81A identified as a stemness-related gene by screening DNA methylation sites based on machine learning-accessed stemness in pancreatic cancer. Last author DOI 10.2217/epi-2022-0098↗
  3. Expression and prognostic analyses of SCAMPs in pancreatic adenocarcinoma. Co-author DOI 10.18632/aging.202377↗
  4. PLS3 predicts poor prognosis in pancreatic cancer and promotes cancer cell proliferation via PI3K/AKT signaling. Co-author DOI 10.1002/jcp.29685↗
  5. High Expression of COL17A1 Predicts Poor Prognosis and Promotes the Tumor Progression via NF-κB Pathway in Pancreatic Adenocarcinoma. Co-author DOI 10.1155/2020/8868245↗
  6. Identification of lncRNAs and Their Functional Network Associated with Chemoresistance in SW1990/GZ Pancreatic Cancer Cells by RNA Sequencing. Co-author DOI 10.1089/dna.2018.4312↗
  7. The involvement of lncRNAs in the development and progression of pancreatic cancer. Co-author DOI 10.1080/15384047.2017.1385682↗
  8. MiR-125a regulates chemo-sensitivity to gemcitabine in human pancreatic cancer cells through targeting A20. First author DOI 10.1093/abbs/gmv129↗
  9. CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine. Co-author DOI 10.18632/oncotarget.7447↗
  10. Marital status independently predicts pancreatic cancer survival in patients treated with surgical resection: an analysis of the SEER database. Co-author DOI 10.18632/oncotarget.8467↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jie J. Yao · 10 shared papers, 2016–2022 · strength 1.06
  2. Jianjun Qian · 8 shared papers, 2016–2022 · strength 0.91
  3. Peng Xu · 7 shared papers, 2016–2021 · strength 0.66
  4. Zechang Xin · 4 shared papers, 2020–2022 · strength 0.51
  5. Duguang Li · 4 shared papers, 2017–2020 · strength 0.39
  6. Yan Du · 3 shared papers, 2020–2021 · strength 0.36
  7. Feiyu Mao · 3 shared papers, 2020–2021 · strength 0.36
  8. Qiang Zhang · 1 shared paper, 2022 · strength 0.17
  9. Lijie Cai · 1 shared paper, 2022 · strength 0.16
  10. Peng Liu · 1 shared paper, 2022 · strength 0.16
  11. Guo‐Qing Jiang · 1 shared paper, 2016 · strength 0.07
  12. Xiao-Dong Wang · 1 shared paper, 2016 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.